Back to results
US 11,596,696 B2Granted
Combination therapy with an anti-CD25 antibody-drug conjugate
AssigneesAdc Therapeutics SA, MedImmune, LLC
InventorsPatricius Hendrikus Cornelis Van Berkel, Lisa Skelton, Francesca Zammarchi, Jay Marshall Feingold, Jens Wuerthner, John Hartley
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
Claims13
A method for treating cancer in an individual, the method comprising administering to the individual an effective amount of ADCX25 and a PD1 antagonist;
- wherein ADCX25 has the following chemical structure:
- and wherein Ab is an antibody that binds to CD25 which comprises (a) a heavy chain having the amino acid sequence of SEQ ID NO. 1, and (b) a light chain having the amino acid sequence of SEQ ID NO. 2.
Dependencies are inferred from the claim text.